6533b85cfe1ef96bd12bcb96
RESEARCH PRODUCT
The effect of the pro-inflammatory cytokine tumor necrosis factor-alpha on human joint capsule myofibroblasts.
Hendrik Schulze-koopsUlrike RitzJochen WollstädterBernhard WatzerChristoph BrochhausenSebastian KuhnStefan G. MattyasovszkyLars Peter MüllerAlexander HofmannPol Maria Rommenssubject
MalePathologymedicine.medical_treatmentFluorescent Antibody TechniqueGene ExpressionDinoprostExtracellular matrixPathogenesisElbow JointImmunology and AllergyCells CulturedReverse Transcriptase Polymerase Chain ReactionAntibodies MonoclonalMiddle AgedImmunohistochemistryExtracellular MatrixCytokinemedicine.anatomical_structureAntirheumatic AgentsCytokinesTumor necrosis factor alphaFemaleHip Jointmedicine.symptomInflammation MediatorsMyofibroblastmusculoskeletal diseasesmedicine.medical_specialtyanimal structuresContractureDiclofenacImmunologyBlotting Westernmacromolecular substancesBiologyCollagen Type IDinoprostoneRheumatologyJoint capsuleResearch articlemedicineHumansAgedCell ProliferationCyclooxygenase 2 InhibitorsTumor Necrosis Factor-alphaProstaglandins FFibroblastsActinsInfliximabCyclooxygenase 2Joint stiffnessContractureJoint Capsuledescription
Introduction Previous studies have shown that the number of myoblastically differentiated fibroblasts known as myofibroblasts (MFs) is significantly increased in stiff joint capsules, indicating their crucial role in the pathogenesis of post-traumatic joint stiffness. Although the mode of MFs' function has been well defined for different diseases associated with tissue fibrosis, the underlying mechanisms of their regulation in the pathogenesis of post-traumatic joint capsule contracture are largely unknown. Methods In this study, we examined the impact of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) on cellular functions of human joint capsule MFs. MFs were challenged with different concentrations of TNF-α with or without both its specifically inactivating antibody infliximab (IFX) and cyclooxygenase-2 (COX2) inhibitor diclofenac. Cell proliferation, gene expression of both alpha-smooth muscle actin (α-SMA) and collagen type I, the synthesis of prostaglandin derivates E2, F1A, and F2A, as well as the ability to contract the extracellular matrix were assayed in monolayers and in a three-dimensional collagen gel contraction model. The α-SMA and COX2 protein expressions were evaluated by immunofluorescence staining and Western blot analysis. Results The results indicate that TNF-α promotes cell viability and proliferation of MFs, but significantly inhibits the contraction of the extracellular matrix in a dose-dependent manner. This effect was associated with downregulation of α-SMA and collagen type I by TNF-α application. Furthermore, we found a significant time-dependent upregulation of prostaglandin E2 synthesis upon TNF-α treatment. The effect of TNF-α on COX2-positive MFs could be specifically prevented by IFX and partially reduced by the COX2 inhibitor diclofenac. Conclusions Our results provide evidence that TNF-α specifically modulates the function of MFs through regulation of prostaglandin E2 synthesis and therefore may play a crucial role in the pathogenesis of joint capsule contractures.
year | journal | country | edition | language |
---|---|---|---|---|
2009-05-16 | Arthritis researchtherapy |